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Abstract
Microsatellite instability (MSI) occurs in 10–20% of colorectal tumours and is associated with good prognosis.
Here we describe the development and validation of a genomic signature that identifies colorectal cancer
patients with MSI caused by DNA mismatch repair deficiency with high accuracy. Microsatellite status for 276
stage II and III colorectal tumours has been determined. Full-genome expression data was used to identify
genes that correlate with MSI status. A subset of these samples (n = 73) had sequencing data for 615 genes
available. An MSI gene signature of 64 genes was developed and validated in two independent validation
sets: the first consisting of frozen samples from 132 stage II patients; and the second consisting of FFPE
samples from the PETACC-3 trial (n = 625). The 64-gene MSI signature identified MSI patients in the first
validation set with a sensitivity of 90.3% and an overall accuracy of 84.8%, with an AUC of 0.942 (95% CI,
0.888–0.975). In the second validation, the signature also showed excellent performance, with a sensitivity
94.3% and an overall accuracy of 90.6%, with an AUC of 0.965 (95% CI, 0.943–0.988). Besides correct
identification of MSI patients, the gene signature identified a group of MSI-like patients that were MSS by
standard assessment but MSI by signature assessment. The MSI-signature could be linked to a deficient MMR
phenotype, as both MSI and MSI-like patients showed a high mutation frequency (8.2% and 6.4% of 615 genes
assayed, respectively) as compared to patients classified as MSS (1.6% mutation frequency). The MSI signature
showed prognostic power in stage II patients (n = 215) with a hazard ratio of 0.252 (p = 0.0145). Patients
with an MSI-like phenotype had also an improved survival when compared to MSS patients. The MSI signature
was translated to a diagnostic microarray and technically and clinically validated in FFPE and frozen samples.
Copyright  2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
There are at least two recognized pathways of
colorectal carcinogenesis [1]. The most common
pathway is a progressive model that involves stepwise
accumulation of genetic alterations in several key
oncogenes and tumour suppressor genes, such as
KRAS, BRAF, TP53 and, importantly, the adenoma-
tous polyposis coli (APC) gene [2,3]. These tumours
account for approximately 85% of all sporadic disease
and commonly display a chromosomal instability
(CIN) phenotype that is associated with widespread
structural alterations. A second class of colon tumours
manifests a microsatellite instability (MSI) phenotype;
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these tumours typically display various insertions or
deletions, most commonly in short tandem repeats,
the so-called microsatellites [4]. MSI is the molecular
fingerprint of a deficient mismatch repair system.
Approximately 15% of colorectal cancers (CRCs)
display MSI, owing either to epigenetic silencing
of MLH1 or to somatic or germline mutations in
one of the mismatch repair genes MLH1, MLH3,
MSH2, MSH6 or PMS2 [5]. Consequently, the MSI
phenotype is also referred to as the deficient MMR
(dMMR) phenotype. MSI rates vary with tumour
stage and, in the adjuvant setting, MSI patients have
been associated with longer survival than patients
with microsatellite-stable (MSS) tumours [6,7]. The
deficiencies in MMR genes lead to loss of function
of tumour suppressor genes and are associated with
activating mutations in oncogenes such as BRAF [8].
Patients with MSI cancers might have different
responses to chemotherapy compared to MSS patients
[1,9]. The MMR involves the recognition and repair
of incorrectly paired nucleotides during DNA repli-
cation. 5-Fluorouracil (5-FU)-based chemotherapy is
the standard treatment for stage II and III CRCs
after surgery, and the survival advantage associated
with this treatment is about 10% [10]. Data from
patients with MSI and from cell lines with dMMR
indicate that MSI promotes resistance to 5-FU treat-
ment [1]. However, results from clinical studies are
conflicting. It seems that MSI patients with stage II
cancer have no benefit from 5-FU treatment [11,12],
while stage III MSI patients might benefit from treat-
ment, but this is predominantly seen in patients that
have a germline predisposition [13]. Evidence sup-
porting the preferential efficacy of irinotecan in MSI
tumours continues to emerge, but are still consid-
ered preliminary [14]. Other studies have shown that
MSI colorectal cancer might be specifically sensitive
to compounds inhibiting the phosphatidylinositol 3-
kinase (PI3K)–AKT–mammalian target of rapamycin
(mTOR) pathway [15].
Considering the different prognosis and treatment
response of MSI patients when compared to MSS
patients, an accurate diagnosis is needed to facili-
tate appropriate treatment decisions. Today, several
methods for the detection of MSI status are used.
MSI can be detected by PCR amplification of specific
microsatellite repeats. The presence of instability is
determined by comparing the length of nucleotide
repeats in tumour cells and normal cells. A consensus
conference established a panel of microsatellite
markers with appropriate sensitivity and specificity to
diagnose MSI [16]. This reference panel, known as
the Bethesda panel, included five microsatellite loci:
two mononucleotides (Bat25 and Bat26) and three
dinucleotides (D5s346, D2s123 and D17s250) [17].
Immunohistochemical analysis of MMR proteins is
an alternative method to detect MSI in the clinical
setting and complements the genetic testing of Lynch
syndrome [18]. Lack of expression of one or more of
the MMR proteins is indicative of deficient MMR, and
can help to determine which gene harbours a germline
mutation or has been inactivated by another mecha-
nism. However, traditional methods for determining
MSI status might not identify all patients with a defi-
cient mismatch repair system and other methods might
be required for a more comprehensive detection [19].
As demonstrated by others [15,20] and in this paper,
patients with MSI have a very distinct gene expres-
sion pattern that allows the development of strong gene
expression signatures. Pairwise comparisons between
studies showed that 94–98% of genes have consis-
tent changes in expression, even though samples were
analysed on different platforms and in different studies
[20]. Here we describe the development and validation
of a robust gene expression signature that identifies
patients with MSI status, determined by standard meth-
ods (PCR, IHC) with high accuracy, and additionally
identifies a group of MSS patients with a MSI-like
phenotype. The signature was translated into a diag-
nostic test that can be used in fresh or FFPE material
and can be performed in combination with other gene
expression signatures [21,22] for further classification
of early-stage colon cancer patients.
Methods
Patients and samples
In this study, microsatellite instability was assessed in
three patient cohorts that have been described previ-
ously: a development cohort (A) [22], a first indepen-
dent validation cohort (B) [23] and a second inde-
pendent cohort in the subset of the PETACC-3 gene
expression dataset with complete MSI status informa-
tion (cohort D) [24–26]. The prognostic value of the
developed MSI signature was assessed on cohort B
combined with an additional set of samples with patient
follow-up data but without hospital-based MSI assess-
ment (cohort C). Patient and sample characteristics are
shown in Table 1. All tissue samples were collected
from patients with appropriate informed consent. The
study was carried out in accordance with the ethical
standards of the Helsinki Declaration and was approved
by the medical ethical boards of the participating med-
ical centres and hospitals.
Hospital-based assessment for microsatellite
instability (MSI)
For the development cohort (cohort A), fresh-frozen
tumour samples from patients with colorectal cancer
were collected (n = 276; Table 1). For 90 patients,
5 µm slides were immunohistochemically stained for
the markers MLH1 and PMS2. For the remaining 186
patients and for all patients in validation cohort B (n
= 132; Table 1) the MSI/MSS status was assessed
by PCR amplification, following the standard proto-
col of the hospital and described in [21,22,26] and in
Supplementary methods (see Supplementary material).
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Table 1. Patient characteristics
Cohorts A B C D Total
Development Validation Validation (prognosis) Validation
Patients (n) 276 132 131 625 1164
Tissue type Fresh Fresh Fresh FFPE
Age
< 70 157 84 60 529 830
≥ 70 119 48 71 96 334
Stage
I 40 – – – 40
II 157 132 131 104 524
III 78 – – 521 599
IV 1 – – – 1
Gender
Male 165 74 66 382 687
Female 111 58 65 243 477
Location
Left colon 143 76 56 391 666
Right colon 96 56 57 234 443
Rectum 37 – 10 – 47
Not available – – 8 – 8
Grade
1 83 1 21 – 105
2 172 90 87 567∗ 916*
3 20 41 21 55∗ 137*
Not available 1 – 2 3 6
BRAF
Activating mutation 24 18 13 46 101
Wild-type/unknown mutation 248 86 92 577 1003
Not available 4 28 26 2 60
Microsatellite stability
MSI 29 31 – 70 130
MSS 247 101 – 555 903
Not available – – 131 – 131
∗ The PETACC3 dataset dichotomized the grade information by grouping stages 1 and 2, and 3 and 4, respectively.
Patients who had at least two microsatellite unstable
markers were defined as MSI. A tumour with only
normal markers was defined as microsatellite-stable
(MSS). MSI assessment of the PETACC-3 samples
(cohort D) was performed as described previously,
using a standard panel of 10 mononucleotide and din-
ucleotide microsatellite loci by PCR amplification of
normal/tumour DNA pairs [26]. Irregularity in one
marker (two in the PETACC-3 study) was defined
as low-grade microsatellite instability (MSI-L); irreg-
ularity in more markers was defined as high-grade
microsatellite instability (MSI) [27]. Patients with MSI-
L were classified as MSS for all analysis.
Development and validation of a 64-gene signature
associated with MSI status
RNA extraction, T7-based linear amplification, Cy-
dye labelling and hybridization to Agilent arrays was
performed as described previously [22]. All tumour
samples contained > 30% tumour cells. Samples were
analysed against a common reference that was gener-
ated using a pool of 44 CRC samples. Gene expres-
sion measurements were normalized (Lowess normal-
ization) and log-ratios were used for identification of
genes that were associated with the MSI status of the
tumours (based on two-sided Student’s t-test). We used
a 10-fold cross-validation (CV10) procedure that has
been described previously [22,28]. The CV10 proce-
dure was applied on the development cohort (n =
276) and repeated 1000 times to determine classifica-
tion performance and for robust gene selection. During
each CV10 round, genes were ranked by p value. The
64 genes (see Supplementary material, Table S1) with
the highest frequency of appearance within the top-
ranking genes in each of the 1000 CV loops were
selected as the final set with the strongest MSI associ-
ation (http://research.agendia.com/).
The 64 gene set was used to construct a nearest
centroid-based classification method (cosine correla-
tion); a MSI gene signature index for the individual
samples was defined as the difference of the two cor-
relations. Samples were classified within the MSI group
if their index exceeded a predefined optimized thresh-
old. This threshold was determined to reach a maximal
overall accuracy (sum of sensitivity and specificity).
The 64-gene signature was validated on 132 inde-
pendent CRC samples analysed in the same way as
the development cohort, using the same microarray
platform and threshold (cohort B, Table 1). Samples
were classified as MSI if their index (the difference
of the two correlations) exceeded the predefined opti-
mized threshold. A second validation was performed
on data from the PETACC-3 study comprising 625
colon tumour FFPE samples with known MSI status,
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Figure 1. (A) A 64-gene expression signature for identification of colorectal cancer samples with MSI, MSI-like and MSS phenotypes.
The MSI signature read-outs (index) are shown for 276 tumour samples (cohort A): red, relative up-regulation; green, down-regulation.
Standard hospital-based MSI assessment is indicated in the middle bars, together with the BRAF V600E mutation status: light grey, MSS
or BRAF wild-type, dark grey, MSI or BRAF mutation. (B) ROC curve and AUC of the signature read-out on validation cohort B. (C) ROC
curve and AUC of the MSI signature on validation cohort D (PETACC-3 study). The optimal sensitivity and specificity (with a sensitivity of
at least 0.9 and sum of sensitivity and specificity is maximal) is indicated in grey.
of which 70 (11.2%) were MSI (cohort D, Table 1). As
described previously [25], these 625 samples had been
hybridized to a custom Affymetrix platform optimized
for analysis of degraded RNA in FFPE samples. We
could identify 58 of the 64 MSI signature genes. Read-
out of the MSI gene signature index on the Affymetrix
data was done in a similar fashion as for the first valida-
tion cohort. A receiver operating characteristic (ROC)
curve was plotted and the area under the ROC curve
(AUC) was calculated. Sensitivity and specificity were
calculated based on the optimal overall accuracy, with
a sensitivity of at least 90%.
Besides the main binary classification of MSS and
MSI samples, a secondary threshold was determined
to subclassify MSI-like samples that were positive by
MSI gene expression signature but typically classified
as MSS by hospital assessment. Both thresholds for
MSI and MSI-like classification were determined using
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the development cohort A only and are indicated in
Figure 1A.
Functional analysis of 64-gene signature
Functional analysis of the genes in the signature was
performed by using the Database for Annotation, Visu-
alization and Integrated Discovery (DAVID) software,
v 6.7 [29]. The enriched functional annotation clusters
were calculated by DAVID through grouping enriched
functional terms. The parameter set used had a similar-
ity threshold of 0.4, multiple linkage threshold of 0.3
and an EASE parameter of 0.5. Only clusters larger
than three functional terms were used.
Investigation of mutation frequency
DNA fragment libraries were prepared using the
TruSeq DNA Sample Preparation Kit (Illumina) and
were hybridized to the SureSelect Human Kinome bait
library according to the manufacturer’s protocol (Agi-
lent). Captured DNA samples were sequenced on a
HiSeq 2000 (Illumina), using a 55 bp paired-end proto-
col. Sequence reads were aligned to the human genome
(GRCh37/hg19) and unique pairs were used for variant
calling. Candidate variants were identified using SAM-
tools and the following inclusion criteria were applied:
minimum coverage 10; minimum variant count 5; a
variant must be detected on both strands. Variants were
assessed using the Ensembl variant effect predictor (v
62) to define those that were likely to impact protein
coding sequences and to filter out germline polymor-
phisms. Matched germline DNA was sequenced for 19
of the 73 tumour samples and an additional 56 normal
samples were used to improve the removal of germline
SNPs and sequencing errors. In this paper we focus on
mutation load; a full analysis of the sequence alter-
ations is the subject of another study.
Statistical and survival analysis
All analyses and statistical tests were performed
in Matlab (MathWorks) or R (v 2.14.1; www.r-
project.org). All tests were two-sided and the signif-
icance level of p values was set to be 0.05. Survival
analysis was performed on cohorts B and C combined,
using Cox proportional hazard models with 10-year
distant metastasis-free survival (dmfs) as end point.
Results
Development of an MSI signature
A cohort of 276 colorectal tumour samples (cohort A,
Table 1) was analysed for their microsatellite status
[microsatellite instability (MSI) or stability (MSS)]
according to the local standard methodology at the
originating hospital (see Methods for details); 11%
(n = 29) of the tumours were identified as MSI
(Table 1). This cohort was used for identification of
genes with expression strongly associated with MSI
status. Using a 10-fold cross-validation procedure,
we identified a set of 64 genes (see Supplementary
material, Table S1) that formed the basis of a single
sample-based classifier to accurately identify MSI
tumours (Figure 1A). Optimal accuracy was reached
upon classification of 57 samples as MSI by the
signature and 219 samples as MSS, corresponding
to a sensitivity of 93.1% and a specificity of 87.9%
(Table 2).
The 64-gene signature was validated in an inde-
pendent cohort of 132 stage II colon cancer samples
(validation cohort B, Table 1) that was analysed using
the single sample predictor (SSP), as established in
the development cohort. Performance in the validation
samples showed an area under the ROC curve (AUC)
of 0.942 (95% CI, 0.888–0.975) with a sensitivity of
90.3% and a specificity of 83.2% when applying the
established threshold for MSS and MSI classification
(Figure 1B, Table 2).
A second independent validation of gene signature
was performed on a prospective cohort of FFPE tissue
samples from the randomized PETACC-3 study (cohort
D, Table 1) [24]. Signature read-out in the PETACC-3
samples showed a very high concordance with hospital-
based MSI assessment, with an ROC of 0.965 (95%
CI, 0.943–0.988), which has an optimal sensitivity of
94.3% and specificity of 90.1% (Figure 1C, Table 2).
Besides validating the signature in an independent
prospective study, this result showed that the developed
64-gene signature can be successfully translated to a
different microarray platform and can likely be used
for MSI assessment on FFPE samples.
MSI signature and mutation frequency
In all patient cohorts, the MSI signature was able to
correctly identify nearly all MSI patients (sensitivity
above 92%) but they were classified as MSI by the
gene signature (Figure 1A). We hypothesized that,
although these MSI-like tumours were assessed as
MSS by standard methods, they do have a deficient
mismatch repair (dMMR)-related phenotype. As such,
the developed gene signature might be able to identify
MSI samples but also MSS samples that harbour a
dMMR phenotype (MSI-likes).
To test this hypothesis, we have deep-sequenced
73 tumour samples for their ‘cancer kinome’ (615
genes in total). The sequencing results confirmed
that samples identified as MSI by the gene signature
have a significantly higher mutation frequency (on
average, candidate mutations were identified in 7.4%
of the analysed genes) compared to MSS samples (on
average, candidate mutations were identified in 1.6% of
the genes) (Student’s t-test, p = 3.15e-12). Importantly,
further classification into MSI and MSI-like samples
indicated that the mutation frequency of the MSI-like
tumours (average 6.4%) is also significantly higher than
that of MSS samples (Student’s t-test, p = 6.26e-6) and
comparable to the mutation frequency in MSI samples
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Table 2. Performance of MSI gene signature: performance of MSI and MSS classification by the 64-gene signature compared to standard
local hospital methodology
Tissue n Sensitivity Specificity Overall accuracy
Development cohort A Fresh 276 93.1 87.9 88.4
Validation cohort B Fresh 132 90.3 83.2 84.8
Validation cohort D (PETTAC-3) FFPE 625 94.3 90.1 90.6
(8.2%) (Figure 2). This result suggests that MSI-like
tumours also harbour a dMMR phenotype, resulting in
a higher mutation rate.
It is important to note that the MSI-like patients, as
identified by the signature, were not patients with a
low-grade MSI (MSI-low) assessment by the hospital
(data not shown), confirming that the MSI-likes might
be a subclass that cannot be identified by standard MSI
assessment.
Investigation of activating mutations in BRAF
showed that 64.3% of all samples classified as MSI
by the gene signature harboured an activating BRAF
mutation (36 of 56 samples with a known BRAF
mutation status). In the MSI-like class, 17.4% of
the samples had an activating BRAF mutation, while
the MSS classified samples were almost exclusively
(98.0%) BRAF wild-type (342 of 349 samples).
Functional annotation
The association between the MSI gene signature and a
dMMR phenotype was further supported by functional
analysis. The results indicated that four functional
annotation clusters were significantly enriched in the 64
signature genes (see Methods; see also Supplementary
material, Tables S1 and S2). Annotation cluster 1
indicated that the encoded proteins of the signature
are enriched with zinc-finger domain proteins, which
are often found as part of transcription, translation,
DNA replication and repair machineries [30]. Together
with the enrichment in functional terms related to
DNA binding and the nucleic acid metabolic processes
(annotation cluster 2), these results are in agreement
with the nature of DNA mismatch repair proteins as
DNA interacting/metabolism partners that often form
large complexes in the nucleus (annotation cluster 4)
[31]. In addition, annotation cluster 3 indicated that the
signature genes are also involved in apoptosis.
MSI-signature and prognosis
The prognostic value of the 64-gene MSI signature was
tested on 263 mostly (80%) untreated stage II tumours:
132 samples from validation cohort B, plus an addi-
tional set of 131 stage II colon tumours with no avail-
able hospital-based MSI assessment (validation cohort
C, Table 1). Patients with samples classified as MSI by
the gene signature showed a significantly better distant
metastasis-free survival (DMFS) compared to patients
with MSS tumours, with a hazard ratio (HR) of 0.252
(95% CI, 0.076–0.83, p = 0.0145) (Figure 3A). After
further subclassification into MSI, MSI-like and MSS,
the MSI-like group also showed a significantly better
survival compared to MSS samples. Interestingly, the
MSI group with concordant MSI classification by sig-
nature and hospital method showed a 100% survival
rate (Figure 3B). In contrast to stage II, investigation
in stage III samples (n = 201) showed no prognostic
value of MSI/MSS classification (p = 0.29) (data not
shown).
It has been postulated that MSI patients might be
resistant to 5-FU treatment and that this resistance is
associated with thymidylate synthase (TYMS) activity.
We therefore investigated the expression of TYMS
in the tumours. Samples classified as MSI showed
a significant higher expression of TYMS compared
to samples classified as MSS (cohort A, p < 1e-
18). Samples classified as MSI-like showed also a
significantly higher expression of TYMS compared to
MSS (p = 3.9e-13) (Figure 4).
Technical validation of the MSI gene signature
The reproducibility of the MSI signature was inves-
tigated by replicate hybridization and analysis of 53
samples. MSI gene signature results were highly repro-
ducible, with an R2 value of 0.992 (Figure 5A)
and, importantly, all samples resulting in the same
classification (100% concordance). Matching samples
from the same patients (n = 60) that were either
preserved as formalin-fixed and paraffin-embedded
(FFPE) or preserved fresh in RNA-retain were analysed
to address tumour heterogeneity and technical differ-
ences between FFPE and fresh preservation. The read-
outs of MSI signature score from these two biopsies
were highly correlated (R = 0.93) and the binary results
(MSS versus MSI) were 98.4% concordant. In addition,
a repeated assessment was performed for three samples
over 20 consecutive days by five different technicians.
Signature read-out was stable across the 20 consecutive
days, with an average standard deviation of well below
5% of the total dynamic range (Figure 5B). Of the 60
measurements, only two read-outs resulted in a change
in classification outcome (96.7% concordance). Finally,
validation of the signature on the PETACC-3 study
(Figure 1C) indicated that the gene signature, which
has been developed and validated on fresh-frozen tissue
samples, can be used for assessment of FFPE samples
as well as fresh tissue.
Discussion
In this report we describe the development of a
64-gene expression signature that identifies patients
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Figure 3. Prognostic value of the 64-gene MSI signature in 263 stage II colorectal cancer (cohorts B and C combined). (A) Kaplan–Meier
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with DNA mismatch repair deficiency resulting in
a MSI phenotype. The signature was developed and
independently validated in large sets of samples and
showed high reproducibility in technical validation
experiments. To our knowledge, this is the first report
to describe a genomic MSI-signature directly linked to
mutation frequency, which was translated into a robust
diagnostic test.
The MSI-signature identifies patients with MSI
status with high accuracy (85% and 91% accuracy in
validation sets B and D, respectively) but also identifies
a group of MSI-like patients who are not recognized by
traditional methods as MSI but have features similar
to MSI patients, eg high mutation frequency, frequent
BRAF mutations, high TYMS expression and better
prognosis. This observation is in good agreement with
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Figure 4. Relative gene expression levels (log10 scale) of thymidy-
late synthase (TYMS) in samples classified asMSS, MSI andMSI-like
by the 64-gene signature. Samples classified as MSI showed a sig-
nificant higher expression of TYMS compared to samples classified
as MSS (p< 1e-18, Student’s t-test) Samples classified as MSI-like
also showed a significantly higher expression of TYMS compared
to MSS (p = 3.9e-13, Student’s t-test).
a recently published study from the Cancer Genome
Atlas (TCGA) Network that also identified a group
of patients with MSI-like features (high mutation
frequency) who were classified as MSS by traditional
methods [19]. This is clinically relevant because
these patients might be better served without adjuvant
chemotherapy if they are stage II. Additionally, these
result indicate that that microsatellite instability is not
necessarily a good surrogate for dMMR in all patients.
Interestingly, in our study, the sample with the
highest mutation frequency (23.8%) is MSI-like by
gene signature but was classified MSS by standard
PCR assessment. This is again in good agreement with
observations from TCGA that found that six patients
with highest mutation rates were classified as MSS
by standard methods. On the other hand, the single
sample that was MSI by standard methods but with
a strong MSS gene expression pattern in our set did
not have an increased mutation rate, suggesting that
this sample was incorrectly classified by standard MSI
assessment (Figure 2).
The more comprehensive identification of MSI and
MSI-like patients might be explained by the fact that
the read-out of gene expression is a measurement of
cellular consequences of DNA MMR deficiency in col-
orectal tumour, and is therefore independent of know-
ing the cause of the defect. At this moment, not all
components of the MMR pathway in human cells are
known, eg the human counterparts of Escherichia coli
MutH and UvrD are not yet identified [31]. Although
the epigenetic silencing of MLH1 is often observed as
the main factor, other factors are known to play a role.
MMR defects can be caused by any genetic or epige-
netic alteration of the genes in the DNA MMR path-
way. Knock-out mouse models of Msh2 , Msh3 , Msh6 ,
Mlh1 , Mlh3 , Pms1 , Pms2 and Exo1 all confer a MSI
phenotype [32,33]. It is therefore difficult to compre-
hensively measure all possible sources causing MMR
deficiency. Moreover, although somatic mutations in
known mismatch-repair genes might be detectable, the
mutations do not always result in microsatellite insta-
bility, at least not in those microsatellites that are
traditionally assessed [19]. However, it is possible to
summarize the cellular consequence of DNA MMR
deficiency with a dominant gene expression pattern,
as with the 64-gene signature, that measures the down-
stream effect. The functional annotation of the 64 genes
further supports the theory that the signature measures
an activation that is caused by MMR deficiency, rather
than the deficiency itself. Proteins with classical con-
served zinc-finger domains, DNA binding domains and
associated to the nucleic acid metabolic processes were
enriched in the signature. The expression signature is
indicative of active DNA damage signalling, which in
turn leads to cell cycle arrest and apoptosis (see Sup-
plementary material, Table S2).
The 64-gene signature summarizes the gene expres-
sion pattern displayed by colorectal tumours with DNA
MMR deficiency, regardless of the diverse causes of
this defect, and therefore might have advantages when
compared to IHC or PCR methods [9]. Using a gene
expression signature for MSI assessment might also
have technical advantages: it does not require a com-
parison of DNA microsatellite regions from paired nor-
mal and tumour tissues; in addition, the nature of a
molecular signature builds upon the read-out of a rela-
tively large set of genes, resulting in robust and repro-
ducible measurements; additionally, the MSI signature
can be read out from the same tissue biopsy and in
the same assay as other diagnostic signatures [20,21],
minimizing sample requirements and systematic errors.
It has been well established that stage II MSI
patients have better prognosis compared to patients
with functional mismatch repair [34]. Consistent with
this knowledge, we report here that tumours predicted
by the 64-gene signature as MSI showed better distant
metastasis-free survival. While the good prognosis of
MSI tumours is well documented, the value of MSI
to predict response to adjuvant chemotherapy is still
under investigation. Cell line models support the idea
that CRCs require a functional MMR system to induce
apoptosis in response to 5-FU treatment [35]. In addi-
tion, meta-analysis of seven independent clinical stud-
ies indicated that MSI patients do not benefit from adju-
vant chemotherapy with 5-FU [12]. The mechanism of
action of 5-FU is through its metabolite dUMP, which
competes for the binding site of thymidylate synthase
(TYMS ), an enzyme catalysing conversion of dUMP to
dTMP during DNA synthesis. The non-responsiveness
to 5-FU therapy in MSI patients might be related to
higher expression of TYMS in these tumours [36]. In
our dataset, we have confirmed this association, as MSI
patients identified by the signature have high expres-
sion of TYMS . MSI-like patients might present an addi-
tional population of CRC patients that are unlikely to
respond to treatment with 5-FU.
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Figure 5. Reproducibility and precision of the 64-gene signature. (A) Replicate analysis of 53 tumour samples shows a very high correlation
in signature index. (B) Stability of the MSI signature read-out for three representative diagnostic samples across a time period of 20
consecutive days. In both panels, the classification threshold (MSI vs MSS) is indicated by the dashed line.
To conclude, we have developed a 64-gene signature
characterizing DNA MMR deficiency in colorectal
tumours. This signature is technically robust and can
be used as an alternative diagnostic tool to assess
MSI status. It was implemented on a diagnostic array
and validated in both fresh-frozen and FFPE tumour
samples. The results from this test provide information
on the prognosis of colorectal cancer patients and
aid decision making for the selection of appropriate
chemotherapeutic agents.
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